How big is Organogenesis Holdings, Inc.?

As of Jun 18, Organogenesis Holdings, Inc. has a market capitalization of 399.33 million and reported net sales of 458.76 million with a net profit of -15.88 million over the latest four quarters.

Market Cap: As of Jun 18, Organogenesis Holdings, Inc. has a market capitalization of 399.33 million, categorized as Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Organogenesis Holdings, Inc. reported net sales of 458.76 million and a net profit of -15.88 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 385.32 million and total assets of 497.89 million.

What does Organogenesis Holdings, Inc. do?

Organogenesis Holdings, Inc. is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine products. As of March 2025, it reported net sales of $87 million and a net loss of $19 million, with a market cap of $399.33 million.

Overview:<BR>Organogenesis Holdings, Inc. is a regenerative medicine company that focuses on the development, manufacture, and commercialization of product solutions for advanced wound care, surgical, and sports medicine markets, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 87 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -19 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 399.33 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: 3.72% <BR>Price to Book: 1.08<BR><BR>Contact Details:<BR>Address: 85 Dan Rd, CANTON MA : 02021-2810 <BR>Tel: 1 781 5750775 <BR>Website: https://investors.organogenesis.com

Should I buy, sell or hold Organogenesis Holdings, Inc.?

Who are in the management team of Organogenesis Holdings, Inc.?

As of March 2022, the management team of Organogenesis Holdings, Inc. includes President and CEO Gary Gillheeney, Directors Maurice Ades and Glenn Nussdorf, and Independent Directors Alan Ades, Albert Erani, and Arthur Leibowitz. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Organogenesis Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Gary Gillheeney, who serves as the President, Chief Executive Officer, and Director.<BR>- Mr. Maurice Ades, who is a Director.<BR>- Mr. Glenn Nussdorf, who is also a Director.<BR>- Mr. Alan Ades, who serves as an Independent Director.<BR>- Mr. Albert Erani, who is an Independent Director.<BR>- Mr. Arthur Leibowitz, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Organogenesis Holdings, Inc. overvalued or undervalued?

As of May 8, 2025, Organogenesis Holdings, Inc. is considered overvalued with a high P/E ratio of 28 and a PEG ratio of 0.32, indicating increased risk compared to its peers, despite a year-to-date return of 48.44% that underperforms the S&P 500.

As of 8 May 2025, the valuation grade for Organogenesis Holdings, Inc. has moved from expensive to risky. Based on the current metrics, the company appears to be overvalued. The P/E ratio stands at 28, significantly higher than the industry average, while the EV to EBITDA ratio is 9.24. Additionally, the PEG ratio is notably low at 0.32, indicating potential overvaluation relative to growth expectations.<BR><BR>In comparison to its peers, Organogenesis has a P/E ratio of 608.59, which is drastically higher than Castle Biosciences, Inc. at -71.36 and Orthofix Medical, Inc. at -4.76. This suggests that Organogenesis is trading at a premium compared to its risky peers. Furthermore, while the company has shown strong returns year-to-date at 48.44%, it has underperformed against the S&P 500 over the last three and five years, which returned 70.41% and 96.61%, respectively. This underperformance reinforces the notion that the stock may be overvalued in the current market context.

Is Organogenesis Holdings, Inc. technically bullish or bearish?

As of September 19, 2025, Organogenesis Holdings, Inc. shows a mildly bullish trend overall, supported by bullish weekly and monthly MACD and KST indicators, though mixed signals from Dow Theory suggest caution.

As of 19 September 2025, the technical trend for Organogenesis Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST also support this stance. The Bollinger Bands indicate a bullish trend on the weekly chart and a mildly bullish trend on the monthly chart. However, the Dow Theory shows a mildly bearish signal on the weekly timeframe, contrasting with a mildly bullish monthly view. The daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the indicators point to a mildly bullish stance, but the mixed signals, particularly from Dow Theory, indicate caution. Multi-period return data is not available for comparison with the S&P 500.